Manila Times Business
Cingulate Receives Complete Response Letter from FDA for CTx-1301
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, to
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Diamond drilling program under way at Leviathan Metals’ Central Project, Kalahari Copper Belt, Botswana
2h ago
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
2h ago
Paychex Small Business Jobs Index Improves for a Third Consecutive Month
2h ago
Safe Pro Awarded U.S. Army Order For AI-Powered Threat Analysis Kit Together with Red Cat Black Widow Drones
2h ago